Publications by authors named "T Sasai"
Autoantibodies are detected in idiopathic interstitial pneumonias (IIPs) without a clear connective tissue disease diagnosis, and their clinical significance is unclear. This study aimed to identify a novel autoantibody in IIPs. We screened 295 IIP patients using a S-methionine labeled protein immunoprecipitation assay.
View Article and Find Full Text PDFArticle Synopsis
- - This study compared juvenile idiopathic inflammatory myopathy (IIM) and adult-IIM by analyzing autoantibodies, clinical characteristics, and drug-free conditions in 320 patients over 20 years.
- - Juvenile-IIM showed a higher rate of achieving drug-free conditions (34%) compared to adult-IIM (18%), with specific autoantibodies like anti-TIF1-γ linked to fewer muscle symptoms and lower malignancy rates in juveniles.
- - Both groups had overlapping features with certain autoantibodies (like anti-MDA-5 and anti-ARS) associated with severe symptoms and a low likelihood of drug-free conditions, while treatment patterns differed notably between the two age groups.
Anti-aminoacyl-tRNA synthetase (ARS) antibodies are myositis-specific antibodies associated with anti-synthetase syndrome (ASSD). Some patients are positive for anti-ARS antibodies on enzyme-linked immunosorbent assay (ELISA) but negative on RNA-immunoprecipitation (RNA-IP) (the gold standard method). Whether these patients should be considered truly positive for anti-ARS antibodies remains unclear.
View Article and Find Full Text PDFA 61-year-old female patient underwent upper gastrointestinal endoscopy, which confirmed the presence of Helicobacter pylori (H. pylori)-positive nodular gastritis (NG). Routine upper gastrointestinal endoscopy after H.
View Article and Find Full Text PDFObjective: Antimelanoma differentiation-associated gene 5 (anti-MDA5)-positive dermatomyositis with interstitial lung disease (DM-ILD) progresses rapidly and has a poor prognosis. Previously, we reported the efficacy of a combination therapy comprising high-dose glucocorticoids (GCs), calcineurin inhibitors (CNIs), and intravenous cyclophosphamide (IV CYC) in a multicenter clinical trial (UMIN000014344). In the present study, we evaluated the long-term outcomes and effects of induction therapy on the maintenance of remission.
View Article and Find Full Text PDF